Letrozole Eg

Letrozole, the active ingredient in Letrozole Eg, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both in early‑stage adjuvant settings and in metastatic disease. GNH USA supplies Letrozole Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways, providing therapeutic benefit in several clinical scenarios.

Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen‑driven tumor growth and improves disease control. Adjuvant therapy for early‑stage HR+ breast cancer: decreases risk of recurrence after surgery. Metastatic HR+ breast cancer: prolongs progression‑free survival and overall disease management.

Letrozole may cause a range of adverse reactions, from mild to severe. Patients should be aware of both common and rare events.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe liver injury (hepatotoxicity) - Bone fractures due to decreased bone mineral density - Pulmonary embolism or deep‑vein thrombosis - Anaphylactic or severe allergic reactions - QT interval prolongation on ECG

When prescribing Letrozole, clinicians should consider several safety measures.

Monitor bone health: assess calcium and vitamin D status regularly and consider supplementation. Assess liver function: obtain baseline liver tests and repeat periodically during therapy. Avoid use in premenopausal women: the drug is indicated for postmenopausal patients only. Review concomitant medications: evaluate for potential interactions with CYP2A6 modulators. Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors: may increase letrozole plasma levels. - Concurrent estrogen replacement therapy: antagonizes therapeutic effect. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Tamoxifen: may reduce letrozole efficacy when used together. - Warfarin: possible alteration of anticoagulant effect, requiring INR monitoring. - Selective serotonin reuptake inhibitors (SSRIs): may affect letrozole metabolism.